Business Standard

Monday, December 23, 2024 | 05:45 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Page 2 - Sanofi

Sanofi to invest 400 million euros in mRNA vaccines development

The mRNA technology has proven both effective and safe so far in the vaccine response to COVID-19, including in response to the virus' variants.

Sanofi to invest 400 million euros in mRNA vaccines development
Updated On : 29 Jun 2021 | 6:57 PM IST

Glaxo gets ready for next pandemic after hiccups in Covid vaccine

Pharma giant is talking with the UK and other governments about building facilities to bring vaccine development onshore before the next crisis.

Glaxo gets ready for next pandemic after hiccups in Covid vaccine
Updated On : 23 May 2021 | 8:50 AM IST

Sanofi, Glaxo covid vaccine works well in mid-stage study, shot on track

Volunteers showed a similar antibody response to people who have recovered from the coronavirus, the companies said in a statement Monday.

Sanofi, Glaxo covid vaccine works well in mid-stage study, shot on track
Updated On : 17 May 2021 | 12:41 PM IST

Drugmaker Sanofi India fourth quarter net profit at Rs 145.9 crore

Drug firm Sanofi India on Tuesday reported a net profit of Rs 145.9 crore for the March ended quarter.

Drugmaker Sanofi India fourth quarter net profit at Rs 145.9 crore
Updated On : 27 Apr 2021 | 7:17 PM IST

At $2.06 per dose, India pays the least for AstraZeneca Covid-19 vaccine

The price paid by different governments for a vaccine dose - including for the same vaccine - varies across countries, Unicef data shows

At $2.06 per dose, India pays the least for AstraZeneca Covid-19 vaccine
Updated On : 29 Mar 2021 | 6:10 AM IST

Bristol-Myers, Sanofi to pay Hawaii $834 mn over Plavix warning label

Bristol-Myers and Sanofi, which produced Plavix in a partnership, in a joint statement vowed to appeal, saying the decision was "unsupported by the law and at odds with the evidence at trial"

Bristol-Myers, Sanofi to pay Hawaii $834 mn over Plavix warning label
Updated On : 16 Feb 2021 | 9:54 AM IST

Sanofi's mRNA Covid-19 vaccine candidate not ready this year, CEO says

In December last year, Sanofi had said it was targeting "earliest potential approval" of the shot in the second half of 2021, following positive preclinical data

Sanofi's mRNA Covid-19 vaccine candidate not ready this year, CEO says
Updated On : 14 Feb 2021 | 6:56 AM IST

Sanofi posts stronger-than-expected result in Q4, eyes more cost cuts

The French company, which stunned investors last year with the delay of a COVID-19 vaccine candidate, confirmed an operating income margin target of 30%

Sanofi posts stronger-than-expected result in Q4, eyes more cost cuts
Updated On : 05 Feb 2021 | 12:48 PM IST

France's Sanofi to help rival Pfizer-BioNTech make coronavirus vaccines

The announcement came as delays or production problems for the Pfizer-BioNTech vaccine and a vaccine from Britain''s AstraZeneca have caused political uproar across the European Union

France's Sanofi to help rival Pfizer-BioNTech make coronavirus vaccines
Updated On : 27 Jan 2021 | 10:08 PM IST

Drugmakers to hike prices for 2021 as Covid pressure puts revenues at risk

Drugmakers including Pfizer Inc, Sanofi SA, and GlaxoSmithKline Plc plan to raise US prices on more than 300 drugs in the United States on Jan 1

Drugmakers to hike prices for 2021 as Covid pressure puts revenues at risk
Updated On : 01 Jan 2021 | 9:08 AM IST

Sanofi-GSK delay Covid-19 vaccine to late 2021 in setback to global fight

The two companies said they planned to start another study next February, hoping to come up with a more effective vaccine

Sanofi-GSK delay Covid-19 vaccine to late 2021 in setback to global fight
Updated On : 12 Dec 2020 | 1:47 AM IST

Sputnik V developers offer to share tech with Sanofi-GSK amid vaccine delay

In late November, the Sputnik V developers also offered foreign vaccine producers their help

Sputnik V developers offer to share tech with Sanofi-GSK amid vaccine delay
Updated On : 11 Dec 2020 | 3:13 PM IST

Sanofi offers to buy Dutch biotechnology firm Kiadis for $358.4 million

Kiadis owns a platform based on a so-called "allogeneic natural killer" that can seek and identify malignant cancer cells

Sanofi offers to buy Dutch biotechnology firm Kiadis for $358.4 million
Updated On : 03 Nov 2020 | 2:00 AM IST

Sanofi India: Long-term investors advised to consider the stock on dips

Analysts see 19 per cent annual growth in earnings during FY20-22 with significant rise in return ratios post sale of a facility

Sanofi India: Long-term investors advised to consider the stock on dips
Updated On : 02 Nov 2020 | 11:54 PM IST

Sanofi, GSK to supply Covax with 200 million doses of coronavirus vaccine

Sanofi and GSK have signed a Statement of Intent with Gavi, a global risk-sharing mechanism for pooled procurement and equitable distribution of eventual Covid-19 vaccines.

Sanofi, GSK to supply Covax with 200 million doses of coronavirus vaccine
Updated On : 29 Oct 2020 | 7:23 AM IST

Sanofi, GSK to provide 200 mn doses of Covid-19 vaccine to global alliance

The facility is part of COVAX, a coalition of governments, health organisations, businesses and charities working to accelerate the development of Covid-19 vaccines

Sanofi, GSK to provide 200 mn doses of Covid-19 vaccine to global alliance
Updated On : 28 Oct 2020 | 2:47 PM IST

World Coronavirus Dispatch: Students across globe returning to classrooms

Boris Johnson earmarks £500 mn for mass rapid testing, Sanofi starts trials of vaccine, Steroids could reduce deaths by a third, and other pandemic-related news across the globe

World Coronavirus Dispatch: Students across globe returning to classrooms
Updated On : 03 Sep 2020 | 6:03 PM IST

Sanofi and GSK launch trial for protein-based coronavirus vaccine

PARIS (Reuters) - French drugmaker Sanofi and its British peer GSK have started a clinical trial for a protein-based COVID-19 vaccine candidate, as pharmaceutical companies race to develop treatments

Sanofi and GSK launch trial for protein-based coronavirus vaccine
Updated On : 03 Sep 2020 | 11:32 AM IST

Pick-up in biosimilar launches driving Biocon's prospects; stock rises 7.8%

As US launch of Insulin addresses a large market, improved visibility for more launches will keep sentiment elevated

Pick-up in biosimilar launches driving Biocon's prospects; stock rises 7.8%
Updated On : 02 Sep 2020 | 3:14 AM IST

Sanofi more confident about its coronavirus vaccines, trials next month

The company is working on two of the more than 150 potential vaccines being developed across the world to tackle the Covid-19 pandemic

Sanofi more confident about its coronavirus vaccines, trials next month
Updated On : 29 Aug 2020 | 8:34 AM IST